AXIN2 and glioblastoma: CAP2 treatment also repressed AXIN2 and LGR5 in human U87 and U251 glioblastoma cells, and AXIN2 and LEF1 in both MeWo human melanoma and H358 human lung cancer cells (since LGR5 was not detected here), with WNT-TCF targets generally regulated in a dose-dependent manner (Fig 1C).